Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May 11;16(10):1838.
doi: 10.3390/cancers16101838.

The Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Elderly Breast Cancer Patients: What Do We Know?

Alexandre Giraudo  1 , Renaud Sabatier  1 , Frederique Rousseau  1 , Alexandre De Nonneville  1 , Anthony Gonçalves  1 , Maud Cecile  1 , Cecile Braticevic  1 , Frederic Viret  1 , Lorene Seguin  1 , Maria Kfoury  1 , Dorothée Naudet  1 , Marie Hamon  2 , Louis Tassy  1
Affiliations
Review

The Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Elderly Breast Cancer Patients: What Do We Know?

Alexandre Giraudo et al. Cancers (Basel). .

Abstract

Background: Breast cancer (BC) incidence increases with age, particularly in HR-positive/HER2-negative subtypes. Cyclin-dependent kinase 4 and 6 inhibitors (CDK 4/6is) alongside endocrine therapy (ET) have emerged as promising treatments for HR-positive/HER2-negative advanced and early BC. However, their efficacy, safety, and impact on quality of life (QoL) in older and frail patients remain underexplored.

Methods: This position paper assesses the existing literature from 2015 to 2024, focusing on CDK4/6is use in patients aged 65 years and older with HR-positive/HER2-negative BC.

Results: Our analysis methodically addresses critical questions regarding the utilization of CDK4/6is in the elderly BC patient population, organizing findings from the metastatic and adjuvant settings. In the metastatic setting, CDK4/6is significantly improve progression-free survival (PFS), paralleling benefits observed in younger patients, and suggest potential overall survival (OS) benefits, warranting further investigation. Despite an increased incidence of grade ≥ 3 adverse events (AEs), such as neutropenia and asthenia, CDK4/6is present a markedly lower toxicity profile compared to traditional chemotherapy, with manageable side effects. QoL analysis indicates that integrating CDK4/6is into treatment regimens does not significantly impact elderly BC patients' daily life and symptom management. Special attention is given to frail subgroups, and personalized approaches are recommended to balance efficacy and adverse effects, such as starting with ET alone and introducing CDK4/6is upon progression in patients with a low disease burden. Transitioning to the adjuvant setting, early results, particularly with abemaciclib, indicate positive effects on disease-free survival (DFS), emphasizing the need for continued analysis to validate these findings and assess long-term implications. However, data on older patients are insufficient to conclude whether they truly benefit from this treatment.

Conclusion: Overall, CDK4/6is present a favorable benefit-risk profile in older BC patients, at least in advanced BC; however, further research is warranted to optimize treatment strategies and improve outcomes in this population.

Keywords: CDK4/6; adjuvant; advanced breast cancer; breast cancer; cyclin-dependent kinase inhibitors; dose adaptation; elderly patients; endocrine therapy; quality of life.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Sun Y.-S., Zhao Z., Yang Z.-N., Xu F., Lu H.-J., Zhu Z.-Y., Shi W., Jiang J., Yao P.-P., Zhu H.-P. Risk Factors and Preventions of Breast Cancer. Int. J. Biol. Sci. 2017;13:1387–1397. doi: 10.7150/ijbs.21635. - DOI - PMC - PubMed
    1. Arnold M., Morgan E., Rumgay H., Mafra A., Singh D., Laversanne M., Vignat J., Gralow J.R., Cardoso F., Siesling S., et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast Edinb. Scotl. 2022;66:15–23. doi: 10.1016/j.breast.2022.08.010. - DOI - PMC - PubMed
    1. Molino A., Giovannini M., Auriemma A., Fiorio E., Mercanti A., Mandarà M., Caldara A., Micciolo R., Pavarana M., Cetto G.L. Pathological, biological and clinical characteristics, and surgical management, of elderly women with breast cancer. Crit. Rev. Oncol. Hematol. 2006;59:226–233. doi: 10.1016/j.critrevonc.2006.01.007. - DOI - PubMed
    1. Gennari A., André F., Barrios C.H., Cortés J., Azambuja E.D., DeMichele A., Dent R., Fenlon D., Gligorov J., Hurvitz S.A., et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann. Oncol. 2021;32:1475–1495. doi: 10.1016/j.annonc.2021.09.019. - DOI - PubMed
    1. ESMO Metastatic Breast Cancer Living Guideline|ESMO. [(accessed on 6 February 2024)]. Available online: https://www.esmo.org/living-guidelines/esmo-metastatic-breast-cancer-liv....